Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(59 sites)
United States
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama University of Southern California, Los Angeles, California Urology Associates of Denver, Lone Tree, Colorado Urological Research Network, Hialeah, Florida Advanced Urology Institute, Largo, Florida Advent Health Orlando, Orlando, Florida Advanced Urology Institute 1, Oxford, Florida H Lee Moffitt Cancer Center, Tampa, Florida Northwestern University, Chicago, Illinois Associated Urological Specialists, Chicago Ridge, Illinois Urology of Indiana, Greenwood, Indiana Urologic Specialists of Northwest Indiana, Merrillville, Indiana University of Kentucky, Lexington, Kentucky Southern Urology LLC, Lafayette, Louisiana Greater Boston Urology, Plymouth, Massachusetts Specialty Clinical Research of St Louis, St Louis, Missouri Hackensack University Medical Center Urology, Hackensack, New Jersey Associated Medical Professionals, Syracuse, New York Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina Central Ohio Urology Group, Gahanna, Ohio Carolina Urologic Research Center, Myrtle Beach, South Carolina Low Country Urology Clinics, North Charleston, South Carolina Urology Associates, Nashville, Tennessee Urology Austin, Austin, Texas Urology San Antonio Research, San Antonio, Texas Canada
Vancouver Prostate Centre Diamond Health Care Centre, Vancouver, British Columbia Nova Scotia Health Authority, Halifax, Nova Scotia St Josephs Healthcare Hamilton, Hamilton, Ontario Princess Margaret Cancer Centre, Toronto, Ontario Germany
Universitatsklinikum Carl Gustav Carus Dresden, Dresden Urologicum Duisburg, Duisburg Universitatsklinikum Frankfurt, Frankfurt am Main Marien hospital Herne, Herne Urologie Neandertal Praxis Mettmann, Mettmann Universitatsklinikum Munster, Münster Universitaetsklinikum Ulm, Ulm Israel
Rambam Medical Center, Haifa Carmel Medical Center, Haifa Rabin Medical Center, Petah Tikva Tel Aviv Sourasky Medical Center, Tel Aviv Japan
National Hospital Organization Kyushu Medical Center, Fukuoka Yamanashi Prefectural Central Hospital, Kofu Osaka General Medical Center, Osaka Toyama University Hospital, Toyama South Korea
National Cancer Center, Goyang-si Chonnam National University Hospital, Gwangju Seoul National University Hospital, Seoul Severance Hospital Yonsei University Health System, Seoul The Catholic University of Korea Seoul St Marys Hospital, Seoul Spain
Fund. Puigvert, Barcelona Hosp Univ Vall D Hebron, Barcelona Hosp Clinic de Barcelona, Barcelona Hosp Reina Sofia, Córdoba Hosp Univ Fund Jimenez Diaz, Madrid Hosp. Univ. 12 de Octubre, Madrid Hosp. Univ. La Paz, Madrid Instituto Valenciano de Oncologia, Valencia